These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21079423)

  • 1. Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?
    Grant AD; Fielding KL; Charalambous S; Chaisson RE; Churchyard GJ
    AIDS; 2010 Nov; 24 Suppl 5():S15-8. PubMed ID: 21079423
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
    Charalambous S; Grant AD; Innes C; Hoffmann CJ; Dowdeswell R; Pienaar J; Fielding KL; Churchyard GJ
    AIDS; 2010 Nov; 24 Suppl 5(0 5):S5-13. PubMed ID: 21079429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing tuberculosis-associated early mortality in antiretroviral treatment programmes in sub-Saharan Africa.
    Lawn SD; Harries AD
    AIDS; 2011 Jul; 25(12):1554-5; author reply 1556. PubMed ID: 21747238
    [No Abstract]   [Full Text] [Related]  

  • 4. Isoniazid preventive therapy for HIV-infected people: evidence to support implementation.
    Eldred LJ; Churchyard G; Durovni B; Godfrey-Faussett P; Grant AD; Getahun H; Chaisson RE
    AIDS; 2010 Nov; 24 Suppl 5():S1-3. PubMed ID: 21079422
    [No Abstract]   [Full Text] [Related]  

  • 5. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions.
    Getahun H; Granich R; Sculier D; Gunneberg C; Blanc L; Nunn P; Raviglione M
    AIDS; 2010 Nov; 24 Suppl 5():S57-65. PubMed ID: 21079430
    [No Abstract]   [Full Text] [Related]  

  • 6. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study.
    Lester R; Hamilton R; Charalambous S; Dwadwa T; Chandler C; Churchyard GJ; Grant AD
    AIDS; 2010 Nov; 24 Suppl 5():S45-8. PubMed ID: 21079427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of tuberculosis in HIV-infected patients.
    Curran A; Falcó V; Pahissa A; Ribera E
    AIDS Rev; 2012; 14(4):231-46. PubMed ID: 23258298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral initiation during or following treatment of TB.
    AIDS Alert; 2010 Jun; 25(6):69-70. PubMed ID: 20623832
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Once-daily anti-HIV therapy in people co-infected with TB.
    TreatmentUpdate; 2004; 16(3):4-5. PubMed ID: 17219607
    [No Abstract]   [Full Text] [Related]  

  • 10. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS.
    Gutierrez EB; Gomes V; Picone CM; Suga H; Atomiya AN
    HIV Med; 2009 Oct; 10(9):564-72. PubMed ID: 19785665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of antituberculosis treatment on virological response to highly active antiretroviral therapy: implications for resource-limited settings?
    Lawn SD; Wood R
    J Infect Dis; 2006 Nov; 194(10):1467-8; author reply 1468. PubMed ID: 17054078
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment.
    Català L; Orcau A; García de Olalla P; Millet JP; Rodríguez-Mondragón A; Caylà JA;
    Int J Tuberc Lung Dis; 2011 Feb; 15(2):263-9, i. PubMed ID: 21219692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.
    Frigati LJ; Kranzer K; Cotton MF; Schaaf HS; Lombard CJ; Zar HJ
    Thorax; 2011 Jun; 66(6):496-501. PubMed ID: 21460373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
    Gordin FM; Matts JP; Miller C; Brown LS; Hafner R; John SL; Klein M; Vaughn A; Besch CL; Perez G; Szabo S; El-Sadr W
    N Engl J Med; 1997 Jul; 337(5):315-20. PubMed ID: 9233868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
    Dheda K; Lampe FC; Johnson MA; Lipman MC
    J Infect Dis; 2004 Nov; 190(9):1670-6. PubMed ID: 15478074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
    Arbeláez MP; Arbeláez A; Gómez RD; Rojas C; Vélez L; Arias SL; Nagles J; Peláez LM; Betancourt G; Velásquez G
    Biomedica; 2007 Dec; 27(4):515-25. PubMed ID: 18320119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.